Liquidia Corp (NASDAQ:LQDA) reported an insider share sale this month as Chief Commercial Officer Scott Moomaw disposed of 10,547 shares of common stock on April 13, 2026. The sales were executed at prices between $38.20 and $38.37, producing gross proceeds of approximately $404,401. The trades were carried out under a pre-arranged Rule 10b5-1 trading plan.
The transaction occurred while Liquidia shares traded near $38.71, after the stock posted a one-year advance of 181%. Independent analysis from InvestingPro cited in company coverage indicates the stock remains below its Fair Value and lists Liquidia among the platform’s most undervalued stocks.
Earlier in April, on April 10, Moomaw also exercised options, acquiring 7,465 shares of Liquidia common stock upon conversion of Performance Stock Units. That exercise and the subsequent sale are distinct actions reported by the company and reflected in recent filings.
Liquidia’s operational results and outlook have been prominent in recent commentary from market analysts. The company disclosed strong fourth-quarter 2025 revenue performance, with sales for its Yutrepia product reaching $90.1 million for the quarter, a 74% increase from the prior quarter. The company indicated revenue guidance that exceeds $1 billion for 2027.
Despite an earnings per share miss for the quarter, Liquidia’s overall revenue and the performance of Yutrepia prompted a number of analyst reactions:
- H.C. Wainwright raised its price target for Liquidia to $55, citing a shift in focus toward profitability.
- BTIG increased its price target to $50, attributing the move to the strong performance of the Yutrepia launch.
- Raymond James maintained a Strong Buy rating with a $47 target, noting Yutrepia’s competitive early launch performance.
- BofA Securities reiterated a Buy rating with a $44 target, highlighting Liquidia’s competitive position in the prostacyclin treatment space.
Market participants will likely continue to weigh insider transactions alongside operational momentum and analyst guidance. The reported sale was placed within a Rule 10b5-1 plan, which indicates the trades were pre-specified and executed according to a pre-arranged schedule rather than opportunistic timing tied to recent public disclosures.
Investors tracking Liquidia will note the juxtaposition of an insider sale against strong product revenue and upward analyst adjustments. The company’s reported Yutrepia revenue and multi-analyst target increases underscore positive commercial traction, while the EPS miss remains a point highlighted in reporting.
With shares trading near $38.71 and InvestingPro analysis flagging the stock as undervalued relative to its Fair Value, Liquidia continues to attract attention from both sell-side analysts and market data platforms. The reported transactions, earnings details, and analyst commentary together form the recent chain of developments for investors to monitor.